---
title: "Mounjaro (tirzepatide), all indications: Pharmacology questions"
description: "Pharmacology questions on Mounjaro (tirzepatide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Mounjaro work (mechanism of action)? How is Mounjaro different from a GLP-1 receptor agonist? How is Mounjaro metabolized? What is the half-life of Mounjaro? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/mounjaro/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Mounjaro (tirzepatide), all indications: Pharmacology questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Mounjaro](https://uspl.lilly.com/mounjaro/mounjaro.html#pi)  
Indication pages: [Type 2 diabetes](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes)

## Mechanism

<a id="mounjaro-mechanism"></a>

### How does Mounjaro work (mechanism of action)?

> “Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.
>
> Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Tirzepatide%20is%20a%20GIP%20receptor,both%20in%20a%20glucose%2Ddependent%20manner.)

> “Tirzepatide lowers fasting and postprandial glucose concentration, decreases food intake, and reduces body weight in patients with type 2 diabetes mellitus.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Tirzepatide%20lowers%20fasting%20and%20postprandial,with%20type%202%20diabetes%20mellitus.)

> “Tirzepatide increases insulin sensitivity, as demonstrated in a hyperinsulinemic euglycemic clamp study after 28 weeks of treatment.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Tirzepatide%20increases%20insulin%20sensitivity%2C%20as,after%2028%20weeks%20of%20treatment.)

> “Tirzepatide reduces fasting and postprandial glucagon concentrations. Tirzepatide 15 mg reduced fasting glucagon concentration by 28% and glucagon AUC after a mixed meal by 43%, compared with no change for placebo after 28 weeks of treatment.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Tirzepatide%20reduces%20fasting%20and%20postprandial,after%2028%20weeks%20of%20treatment.)

> “Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time. Tirzepatide slows post-meal glucose absorption and reduces postprandial glucose.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Tirzepatide%20delays%20gastric%20emptying.%20The,absorption%20and%20reduces%20postprandial%20glucose.)

<a id="mounjaro-vs-glp1-agonist"></a>

### How is Mounjaro different from a GLP-1 receptor agonist?

> “The native incretin hormones—GIP and GLP-1—bind to their respective receptors on beta cells in the pancreas to enhance insulin release.
>
> Mounjaro is a single peptide designed from the structure of native GIP and modified to bind to the GIP and GLP-1 receptors.
>
> While the activity of Mounjaro on the GLP-1 receptor is lower than the activity of the native GLP-1 hormone, the activity of Mounjaro on the GIP receptor is similar to that of the native GIP hormone.”

Source: [MOUNJARO: How Mounjaro® Works, captured 2026-11-12](https://mounjaro.lilly.com/hcp/how-mounjaro-works#:~:text=The%20native%20incretin%20hormones%E2%80%94GIP%20and,of%20the%20native%20GIP%20hormone.)

On the page, select: Video transcript

> “Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Tirzepatide%20is%20based%20on%20the,the%20empirical%20formula%20is%20C225H348N48O68.)

Note: The first passage is from the video transcript on the How Mounjaro Works page of the Mounjaro HCP site; the second is from the Description section of the Prescribing Information.

## Pharmacokinetics

<a id="mounjaro-metabolism"></a>

### How is Mounjaro metabolized?

> “Metabolism
>
> Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid and amide hydrolysis.
>
> Excretion
>
> The primary excretion routes of tirzepatide metabolites are via urine and feces. Intact tirzepatide is not observed in urine or feces.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Metabolism,observed%20in%20urine%20or%20feces.)

<a id="mounjaro-half-life"></a>

### What is the half-life of Mounjaro?

> “The apparent population mean clearance of tirzepatide is 0.061 L/h with an elimination half-life of approximately 5 days, enabling once-weekly dosing.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=The%20apparent%20population%20mean%20clearance,5%20days%2C%20enabling%20once%2Dweekly%20dosing.)

> “It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=It%20contains%20a%20C20%20fatty,binding%20and%20prolongs%20the%20half%2Dlife.)

> “Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Steady%2Dstate%20plasma%20tirzepatide%20concentrations%20were,weeks%20of%20once%20weekly%20administration.)

> “Following subcutaneous administration, the time to maximum plasma concentration of tirzepatide ranges from 8 to 72 hours. The mean absolute bioavailability of tirzepatide following subcutaneous administration is 80%. Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Following%20subcutaneous%20administration%2C%20the%20time,abdomen%2C%20thigh%2C%20or%20upper%20arm.)

## Components

<a id="mounjaro-inactive-ingredients"></a>

### What are the inactive ingredients in Mounjaro?

> “MOUNJARO is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. MOUNJARO has a pH of 6.5 to 7.5.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=MOUNJARO%20is%20a%20clear%2C%20colorless,pH%20of%206.5%20to%207.5.)

## Related pages
- [Medical information: Mounjaro (tirzepatide): All indications](https://www.evicenter.com/medical-information/mounjaro)
- [Indication](https://www.evicenter.com/medical-information/mounjaro/indication)
- [Safety](https://www.evicenter.com/medical-information/mounjaro/safety)
- [Specific populations](https://www.evicenter.com/medical-information/mounjaro/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/mounjaro/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/mounjaro/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/mounjaro/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/mounjaro/access-and-coverage)
